Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
13,303 total articles
Entities tied to GEC Partners III LP sold a combined $24,774,750 of Flowco Holdings Inc. (NASDAQ: FLOC) Class A common stock on March 26, 2026, at $21.175 per share, while simultaneously acquiring equivalent amounts through conversion of LLC interests. The stock trades at $20.69 with a $1.86 billion market capitalization, and InvestingPro's Fair Va…
Bethany Cavanagh, Beam Therapeutics' SVP of Finance and Treasurer, sold 3,242 shares on April 1, 2026, under a Rule 10b5-1 plan to meet tax withholding obligations tied to RSU vesting. The transaction totaled $79,688. Beam has recently disclosed clinical data from its BEACON sickle cell program and BEAM-302 alpha-1 antitrypsin deficiency study, pro…
Christine Bellon, Chief Legal Officer of Beam Therapeutics (NASDAQ: BEAM), sold 5,956 shares on April 1, 2026, in an automatic transaction to meet tax withholding obligations tied to vested restricted stock units. The sale, carried out under a Rule 10b5-1 plan adopted in May 2023, generated $146,398 at $24.58 per share. Beam has recently disclosed …
Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain sold 4,170 Class A shares on April 6, 2026, for roughly $56,013 under a 10b5-1 plan. The transaction leaves Lorrain with 147,712 directly held shares and 6,842 indirectly held through his spouse. The stock trades at $13.44, Company market capitalization is $502 million and the balanc…
Giuseppe Ciaramella, president of Beam Therapeutics (BEAM), sold 11,810 shares on April 1, 2026, for $24.58 per share, netting roughly $290,289. The sale was an automatic disposition to satisfy tax withholding tied to restricted stock unit vesting under a Rule 10b5-1 plan adopted in May 2023. The company’s shares have risen 59% over the past year b…
Guidewire Software CEO Michael George Rosenbaum sold 1,200 shares on April 6, 2026 under a pre-arranged 10b5-1 plan, generating roughly $181,367. The transaction follows a quarter of outperformance and raised fiscal 2026 guidance even as the stock has fallen materially in recent months and some analysts trimmed price targets amid valuation concerns…
Entities affiliated with GEC Advisors LLC sold a total of 7,800,000 shares of Flowco Holdings Inc. (FLOC) on March 26, 2026, at $21.175 per share, generating $165,165,000. The transactions coincided with conversions of LLC Interests into Class A common stock by the same entities and follow a planned secondary offering in which affiliates marketed 7…
A 10% owner of Clene Inc. sold roughly $120,000 of stock on April 2, 2026, while the company announced regulatory and financing milestones tied to its investigational ALS therapy CNM-Au8. The sale leaves the insider with just over 401,000 shares held through SymBiosis II, LLC. Separately, Clene received an in-person Type C meeting with the FDA to r…
Elizabeth Leykum, a member of Lands' End Inc.'s board, sold 935 shares on April 1, 2026, in a transaction tied to a tender offer, generating $42,075. The sale occurred at $45.00 per share, well above the company's prevailing market price of $10.90. Lands' End reported fiscal 2025 fourth-quarter results that missed analyst projections on both earnin…
Director John McClain reported the sale of 840 shares of Lands' End common stock on April 1, 2026, in a Form 4 filing with the SEC. The shares were sold at $45.00 each under a tender offer from LEWHP, LLC - a wholly owned indirect subsidiary of WH Topco, L.P. The transaction totaled $37,800. Lands' End's recent fourth-quarter fiscal 2025 results fe…
Snowflake Inc. director Michael L. Speiser sold 50,034 shares on April 6, 2026, generating $7,520,069 in proceeds under a pre-arranged 10b5-1 plan. The transactions were executed across multiple trades at prices between $148.00 and $148.50, averaging $148.205 per share. Separately, Snowflake appointed Jonathan Beaulier as Chief Revenue Officer, a m…
Director Harit Talwar purchased 5,000 shares of Better Home & Finance Holding Co Class A common stock on April 2, 2026, for $176,218 at a weighted average price of $35.2436. The company also boosted its warehouse credit capacity, expanded mortgage offerings with a Coinbase partnership enabling Bitcoin- and USDC-backed down payments, and appointed H…
Golden Lee Scott, Executive Vice President and Chief Medical Officer of PTC Therapeutics (PTCT), sold 829 shares on April 2, 2026, for $67.99 each to satisfy tax-withholding obligations tied to the vesting of 2,100 restricted stock units granted in April 2023. The transaction reduced Scott's direct holdings to 79,115 shares. The company recently re…
Cardlytics Inc. Chief Executive Officer Amit Gupta disposed of 69,833 shares on April 6, 2026, in a transaction valued at $82,891, according to a Form 4 filing. The sale, executed to meet tax liabilities from restricted stock units that vested on April 1, 2026, leaves Gupta with 987,387 shares. The company recently reported mixed fiscal 2025 Q4 res…
Josephine Linden, a director of Lands’ End, Inc. (NASDAQ: LE), sold 3,482 shares on April 1, 2026 at $45.00 per share, for total proceeds of $156,690, according to a Form 4 filed with the Securities and Exchange Commission. The transaction was executed under a $45-per-share tender offer by LEWHP, LLC, an indirect wholly owned subsidiary of WH Topco…
Director Gordon Hartogensis sold 752 shares of Lands’ End common stock on April 1, 2026, for $45.00 per share, totaling $33,840. After the sale he directly holds 9,142 shares. The company’s shares have since fallen to $10.90, a year-to-date decline of about 21%. InvestingPro places a fair value on the stock at $14.90. Lands’ End reported fiscal 202…
Compass Diversified Holdings CFO Stephen Keller completed an indirect purchase of 30,000 shares of Compass Diversified Holdings (NYSE: CODI) on April 6, 2026, executing the transactions through retirement accounts at prices between $8.50 and $8.6619 per share for a total value of about $258,237. The trades come amid recent stock strength and as the…
Peter L. Gray, who serves as PRES LE Licensing, CAO & GC at Lands' End, Inc. (NASDAQ: LE), completed a set of equity transactions on April 1, 2026, including a sale of 11,454 shares for $515,430, option exercises and the receipt of performance-based restricted stock units. The company recently reported fourth-quarter fiscal 2025 results that missed…
Director Pauls Matthew sold 786 shares of Pelthos Therapeutics Inc. (NASDAQ:PTHS) on April 2, 2026, in two trades totaling roughly $16,439. The disposals were executed under a Rule 10b5-1 plan established December 16, 2025, to meet estimated tax obligations from the vesting of restricted stock units. The company recently reported a Q4 2025 earnings…
Richard Malamut, a director at Pelthos Therapeutics Inc (NASDAQ: PTHS), sold 590 shares on April 2, 2026, in two transactions totaling $12,340, according to a Form 4 filing. The disposals were carried out under a Rule 10b5-1 trading plan established December 16, 2025, to cover estimated taxes related to vesting restricted stock units. The company r…
Pelthos Therapeutics director Ezra M. Friedberg disposed of 558 shares of the company's common stock on April 2, 2026, under a Rule 10b5-1 plan to cover estimated tax liabilities tied to vesting restricted stock units. The combined transactions totaled $11,670. The company has reported a sharp quarterly earnings miss but showed sequential revenue g…
Michele Kim Connors, general counsel of Ambiq Micro, completed two stock sales on April 2, 2026, disposing of a total of 811 shares for $21,209 to meet tax obligations associated with previously reported restricted stock units. The trades occurred at prices between $25.55 and $26.68. Ambiq Micro's shares have climbed 20% over the last week and curr…
Kym Maas, President of LE Consumer and Chief Commercial Officer at Lands' End, sold 1,440 shares of company stock on April 1, 2026, for $64,800. On the same day Maas received shares through the exercise of restricted stock units and a performance-based retention award at no cost, and disposed of additional shares to cover tax obligations. Separatel…
Steven M. Chaouki, TransUnion's President of U.S. Markets, sold 5,000 shares on April 2, 2026, under a pre-arranged Rule 10b5-1 plan for $350,000. The share price at execution was $70.00; the stock trades near its 52-week low and is down 19% year-to-date. TransUnion has completed an acquisition adding AI-enabled telecom capabilities and set medium-…
Pelthos Therapeutics director Peter Greenleaf sold 797 shares of company stock on April 2, 2026, under a pre-arranged 10b5-1 plan for $16,669. The company posted a fourth-quarter 2025 EPS well below expectations, though quarterly revenue and 2025 net product revenue climbed on the back of a mid-year product launch. Analyst coverage was unchanged in…
